Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response

PURPOSE: Although recombinant human interleukin-15 (rhIL-15) has generated much excitement as an immunotherapeutic agent for cancer, activity in human clinical trials has been modest to date, in part due to the risks of toxicity with significant dose escalation. Since pulmonary metastases are a majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebhun, Robert B, York, Daniel, Cruz, Sylvia Margret, Judge, Sean J, Razmara, Aryana M, Farley, Lauren E, Brady, Rachel V, Johnson, Eric G, Burton, Jenna H, Willcox, Jennifer, Wittenburg, Luke A, Woolard, Kevin, Dunai, Cordelia, Stewart, Susan L, Sparger, Ellen E, Withers, Sita S, Gingrich, Alicia A, Skorupski, Katherine A, Al-Nadaf, Sami, LeJeune, Amandine T, Culp, William TN, Murphy, William J, Kent, Michael S, Canter, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174838/
https://www.ncbi.nlm.nih.gov/pubmed/35680383
http://dx.doi.org/10.1136/jitc-2022-004493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174838/
https://www.ncbi.nlm.nih.gov/pubmed/35680383
http://dx.doi.org/10.1136/jitc-2022-004493

Ejemplares similares